ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,00%
Bitcoin
62.668,87
-0,35%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Jazz Pharmaceuticals PLC (JAZZ)

  7. Jazz Pharmaceuticals PLC (JAZZ) News

JAZZ Jazz Pharmaceuticals PLC

110,01
0,72 (0,66%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Jazz Pharmaceuticals PLC JAZZ NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,72 0,66% 110,01 00:45:55
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
110,14 108,58 111,55 110,01 109,29
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
01.5.202422:10PRNUSJazz Pharmaceuticals to Participate in the BofA Securities..
01.5.202422:05PRNUSJazz Pharmaceuticals Announces First Quarter 2024 Financial..
24.4.202422:05PRNUSJazz Pharmaceuticals to Present Data Across Growing Oncology..
17.4.202422:15PRNUSJazz Pharmaceuticals to Report 2024 First Quarter Financial..
10.4.202413:45PRNUSJazz Pharmaceuticals to Showcase Expansive Neuroscience..
02.4.202413:30PRNUSJazz Pharmaceuticals Completes Zanidatamab Biologics License..
12.3.202421:15PRNUSJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on..
09.3.202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202403:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202403:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202403:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202400:09EDGAR2Form 144 - Report of proposed sale of securities
06.3.202401:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202401:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
01.3.202421:11EDGAR2Form 144 - Report of proposed sale of securities
28.2.202422:06EDGAR2Form 8-K - Current report
28.2.202422:05PRNUSJazz Pharmaceuticals Announces Full Year and Fourth Quarter..
27.2.202413:45EDGAR2Form 8-K - Current report
27.2.202413:45PRNUSJazz Pharmaceuticals Appoints Patrick Kennedy to its Board..
21.2.202413:46EDGAR2Form 8-K - Current report
21.2.202413:45PRNUSJazz Pharmaceuticals Appoints Philip Johnson as Chief..
20.2.202422:15PRNUSJazz Pharmaceuticals to Participate in Upcoming March..
14.2.202422:15PRNUSJazz Pharmaceuticals to Report 2023 Full Year and Fourth..
07.2.202408:00PRNUSJazz Pharmaceuticals Enters Definitive Agreement with Redx..
25.1.202423:01EDGAR2Form 8-K - Current report
24.1.202415:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
20.1.202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202400:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202400:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202400:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:45EDGAR2Form 8-K - Current report
21.12.202322:05PRNUSJazz Pharmaceuticals Provides Update on Phase 2 Trial of..
20.12.202322:15PRNUSJazz Pharmaceuticals to Present at the 42nd Annual J.P...
15.12.202313:45EDGAR2Form 8-K - Current report
08.12.202319:20PRNUSJazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS..
06.12.202322:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.12.202315:02PRNUSJazz Pharmaceuticals to Present Long-Term and Real-World..
30.11.202313:45PRNUSJazz Pharmaceuticals to Present New Data Highlighting..
14.11.202308:00BWAutifony Announces Exclusive Global License and..
08.11.202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
JAZZ
Jazz Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten